Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety Study of the Combination of Panitumumab, Irinotecan and Everolimus in the Treatment of Advanced Colorectal Cancer (PIE)

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2014 by The Queen Elizabeth Hospital
Sponsor:
Collaborators:
Amgen
Novartis
Information provided by (Responsible Party):
Amanda Townsend, The Queen Elizabeth Hospital
ClinicalTrials.gov Identifier:
NCT01139138
First received: May 28, 2010
Last updated: November 3, 2014
Last verified: November 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: June 2017
  Estimated Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)